JP2008518013A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008518013A5 JP2008518013A5 JP2007539030A JP2007539030A JP2008518013A5 JP 2008518013 A5 JP2008518013 A5 JP 2008518013A5 JP 2007539030 A JP2007539030 A JP 2007539030A JP 2007539030 A JP2007539030 A JP 2007539030A JP 2008518013 A5 JP2008518013 A5 JP 2008518013A5
- Authority
- JP
- Japan
- Prior art keywords
- colitis
- compound
- prostaglandin
- disease
- thienyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 19
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 12
- 206010009887 colitis Diseases 0.000 claims 11
- 239000000556 agonist Substances 0.000 claims 8
- -1 glucoside ester Chemical class 0.000 claims 8
- 150000003180 prostaglandins Chemical class 0.000 claims 8
- 239000000651 prodrug Substances 0.000 claims 7
- 229940002612 prodrug Drugs 0.000 claims 7
- 208000011231 Crohn disease Diseases 0.000 claims 6
- 150000001408 amides Chemical class 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 5
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 4
- 206010009900 Colitis ulcerative Diseases 0.000 claims 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 3
- 150000002148 esters Chemical class 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims 2
- 206010001985 Amoebic colitis Diseases 0.000 claims 2
- 102000008186 Collagen Human genes 0.000 claims 2
- 108010035532 Collagen Proteins 0.000 claims 2
- 206010014896 Enterocolitis haemorrhagic Diseases 0.000 claims 2
- 238000009825 accumulation Methods 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 235000010290 biphenyl Nutrition 0.000 claims 2
- 239000004305 biphenyl Substances 0.000 claims 2
- 229920001436 collagen Polymers 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 125000001624 naphthyl group Chemical group 0.000 claims 2
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims 1
- 229920000858 Cyclodextrin Polymers 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000006269 biphenyl-2-yl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1=C(*)C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 230000000112 colonic effect Effects 0.000 claims 1
- 229930182478 glucoside Natural products 0.000 claims 1
- 229930182480 glucuronide Natural products 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000004682 mucosal barrier function Effects 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 0 CC(C)(C([C@@](C1*C(O)=O)C(C)=C(C)IC*)O)C1=O Chemical compound CC(C)(C([C@@](C1*C(O)=O)C(C)=C(C)IC*)O)C1=O 0.000 description 3
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62242204P | 2004-10-26 | 2004-10-26 | |
| PCT/US2005/038303 WO2006047476A2 (en) | 2004-10-26 | 2005-10-24 | Therapeutic and delivery methods of prostaglandin ep4 agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008518013A JP2008518013A (ja) | 2008-05-29 |
| JP2008518013A5 true JP2008518013A5 (https=) | 2008-12-25 |
Family
ID=35840538
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007539030A Pending JP2008518013A (ja) | 2004-10-26 | 2005-10-24 | プロスタグランジンｅｐ４アゴニストによる処置方法およびデリバリー方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20080132543A1 (https=) |
| EP (1) | EP1805139A2 (https=) |
| JP (1) | JP2008518013A (https=) |
| AU (1) | AU2005299473B2 (https=) |
| BR (1) | BRPI0518242A2 (https=) |
| CA (1) | CA2585367A1 (https=) |
| WO (1) | WO2006047476A2 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006052893A2 (en) * | 2004-11-08 | 2006-05-18 | Allergan, Inc. | Substituted pyrrolidone compounds as ep4 agonists |
| US20060281818A1 (en) * | 2005-03-21 | 2006-12-14 | Sucampo Ag, North Carolina State University | Method for treating mucosal disorders |
| US20070232660A1 (en) * | 2006-04-04 | 2007-10-04 | Allergan, Inc. | Therapeutic and delivery methods of prostaglandin ep4 agonists |
| EP2120962A1 (en) * | 2006-12-18 | 2009-11-25 | Allergan, Inc. | Methods and compositions for treating gastrointestinal disorders |
| WO2010108028A2 (en) | 2009-03-19 | 2010-09-23 | Fate Therapeutics, Inc. | Compositions comprising cyclic amp enhancers and/or ep ligands, and methods of preparing and using the same |
| WO2011047048A1 (en) | 2009-10-14 | 2011-04-21 | Gemmus Pharma, Inc. | Combination therapy treatment for viral infections |
| ES2654994T3 (es) | 2010-08-12 | 2018-02-15 | Fate Therapeutics, Inc. | Terapia mejorada con células madre y precursoras hematopoyéticas |
| US20120259413A1 (en) * | 2011-04-07 | 2012-10-11 | Allergan, Inc. | Devices, compositions and methods utilizing ep4 and ep2 receptor agonists for preventing, reducing or treating capsular contracture |
| ES2769270T3 (es) | 2011-09-30 | 2020-06-25 | Bluebird Bio Inc | Compuestos para transducción viral mejorada |
| EP2785350B1 (en) | 2011-12-02 | 2018-05-02 | Fate Therapeutics, Inc. | Improved methods of treating ischemia |
| JP6220791B2 (ja) | 2011-12-02 | 2017-10-25 | フェイト セラピューティクス，インコーポレイテッド | 増強された幹細胞組成物 |
| WO2014150602A1 (en) | 2013-03-15 | 2014-09-25 | Fate Therapeutics, Inc. | Cell potency assay for therapeutic potential |
| US9943545B2 (en) | 2013-03-15 | 2018-04-17 | Fate Therapeutics, Inc. | Stem cell culture media and methods of enhancing cell survival |
| AU2014305843B2 (en) | 2013-08-09 | 2019-08-29 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
| IL261002B2 (en) | 2016-02-12 | 2024-07-01 | Bluebird Bio Inc | Vcn enhancer compositions and methods of using the same |
| WO2017139561A1 (en) | 2016-02-12 | 2017-08-17 | Bluebird Bio, Inc. | Vcn enhancer compositions and methods of using the same |
| EP4706758A3 (en) | 2019-05-21 | 2026-05-06 | Ardelyx, Inc. | Methods for inhibiting phosphate transport |
| GB202211232D0 (en) | 2022-08-02 | 2022-09-14 | Heptares Therapeutics Ltd | Prostaglandin EP4 receptor agonist compounds |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5714346B2 (https=) * | 1973-07-12 | 1982-03-24 | ||
| KR880012221A (ko) * | 1987-04-13 | 1988-11-26 | 사노 가즈오 | 에스테르 또는 아미드를 활성성분으로 함유하는 약제 조성물 |
| US6043275A (en) * | 1998-04-16 | 2000-03-28 | Ono Pharmaceutical Co., Ltd. | 3,7-dithiaprostanoic acid derivative |
| TWI249520B (en) * | 1998-07-15 | 2006-02-21 | Ono Pharmaceutical Co | 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient |
| US6586468B1 (en) * | 1998-09-14 | 2003-07-01 | Ono Pharmaceutical Co., Ltd. | ω-substituted phenyl-prostaglandin E derivatives and drugs containing the same as the active ingredient |
| US20020002140A1 (en) * | 2000-01-14 | 2002-01-03 | Holick Michael F. | Novel bisphosphonates and uses thereof |
| PT1339678E (pt) * | 2000-11-27 | 2007-11-30 | Pfizer Prod Inc | Agonistas selectivos do receptor ep4 no tratamento de osteoporose |
| US20030027853A1 (en) * | 2001-06-14 | 2003-02-06 | Allergan Sales, Inc. | 3, 7or3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure |
| US20050222094A1 (en) * | 2001-06-14 | 2005-10-06 | Burk Robert M | Treatment of inflammatory bowel disease |
| ES2254726T3 (es) * | 2001-07-16 | 2006-06-16 | F. Hoffmann-La Roche Ag | Analogos de prostaglandina como agonistas receptores de ep4. |
| NZ530885A (en) * | 2001-07-23 | 2007-09-28 | Ono Pharmaceutical Co | Remedies for diseases with bone mass loss having EP4 agonist as the active ingredient |
| CA2478653A1 (en) * | 2002-03-18 | 2003-09-25 | Pfizer Products Inc. | Methods of treatment with selective ep4 receptor agonists |
| US7053085B2 (en) * | 2003-03-26 | 2006-05-30 | Merck & Co. Inc. | EP4 receptor agonist, compositions and methods thereof |
| RU2311409C2 (ru) * | 2003-01-10 | 2007-11-27 | Ф.Хоффманн-Ля Рош Аг | Производные 2-пиперидона в качестве агонистов простагландина |
| JP5319065B2 (ja) * | 2003-02-11 | 2013-10-16 | アラーガン インコーポレイテッド | 眼圧降下剤としての１０，１０−ジアルキルプロスタン酸誘導体 |
| US6875787B2 (en) * | 2003-02-11 | 2005-04-05 | Allergan, Inc. | 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure |
-
2005
- 2005-10-24 JP JP2007539030A patent/JP2008518013A/ja active Pending
- 2005-10-24 CA CA002585367A patent/CA2585367A1/en not_active Abandoned
- 2005-10-24 US US11/574,528 patent/US20080132543A1/en not_active Abandoned
- 2005-10-24 EP EP05817142A patent/EP1805139A2/en not_active Withdrawn
- 2005-10-24 AU AU2005299473A patent/AU2005299473B2/en not_active Ceased
- 2005-10-24 BR BRPI0518242-5A patent/BRPI0518242A2/pt not_active Application Discontinuation
- 2005-10-24 WO PCT/US2005/038303 patent/WO2006047476A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008518013A5 (https=) | ||
| JP2009543795A5 (https=) | ||
| JP4807884B2 (ja) | 新規チオフェン誘導体 | |
| JP2009540009A5 (https=) | ||
| KR101276449B1 (ko) | 치료제로서의 치환된 감마 락탐 | |
| JP2009543792A5 (https=) | ||
| JP2010500976A5 (https=) | ||
| JP5247680B2 (ja) | １２−アリールまたはヘテロアリールプロスタグランジンアナログ | |
| US20070129552A1 (en) | Therapeutic Substituted Cyclopentanes | |
| JP2014530900A5 (https=) | ||
| JP2014521744A5 (https=) | ||
| JP5410438B2 (ja) | 治療用置換ラクタム類 | |
| JP5532302B2 (ja) | 治療化合物 | |
| JP2011500818A5 (https=) | ||
| BRPI0713806A2 (pt) | lactámicos gama substituìdos como agentes terapêuticos | |
| WO2008008660B1 (en) | Cyclopentane derivatives as antiglaucoma agents | |
| JP2014508106A (ja) | スフィンゴシン−１−リン酸−１受容体モジュレーターとしてのアルキンおよびアルケン誘導体 | |
| EP2170345A1 (en) | Therapeutic substituted cyclopentanes for reducing intraocular pressure | |
| JP2008520737A5 (https=) | ||
| KR101227808B1 (ko) | 고안압 질환을 처치하기 위한 치환된 시클로펜탄 또는시클로펜탄온 | |
| JP2009536967A5 (https=) | ||
| JP2009535418A5 (https=) | ||
| BRPI0808377B1 (pt) | composto, composição e uso de um composto | |
| JP2010516817A5 (https=) | ||
| JP2009535421A5 (https=) |